Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Encouraging early detection and breaking the silence around men’s health
The company has received approval from DCGI to begin patient enrolment and dosing in the country
The company is bringing precision therapies for gynaecological cancers
The submission is supported by positive results from the Phase 3 AMPLIFY trial
cSCC is one of the most common cancers in the U.S. and globally
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Subscribe To Our Newsletter & Stay Updated
